Kymera Therapeutics (NASDAQ:KYMR) Director Jeffrey Albers Sells 5,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Jeffrey Albers sold 5,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Kymera Therapeutics Trading Up 41.5%

Shares of KYMR stock opened at $94.30 on Tuesday. The firm has a fifty day simple moving average of $62.19 and a two-hundred day simple moving average of $50.50. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The firm has a market capitalization of $6.78 billion, a PE ratio of -26.27 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The business had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on KYMR. Mizuho started coverage on Kymera Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $81.00 price objective for the company. Wells Fargo & Company upped their price target on Kymera Therapeutics from $53.00 to $69.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. UBS Group set a $90.00 price target on Kymera Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 26th. Oppenheimer reaffirmed an “outperform” rating and set a $67.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, November 4th. Finally, HC Wainwright increased their target price on shares of Kymera Therapeutics from $70.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $81.68.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Kymera Therapeutics by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock valued at $143,183,000 after purchasing an additional 344,080 shares during the period. Invesco Ltd. grew its position in Kymera Therapeutics by 36.9% during the first quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock valued at $1,152,000 after buying an additional 11,343 shares during the period. Nuveen LLC bought a new position in Kymera Therapeutics during the first quarter valued at about $3,920,000. Russell Investments Group Ltd. increased its holdings in Kymera Therapeutics by 40.0% during the first quarter. Russell Investments Group Ltd. now owns 82,507 shares of the company’s stock worth $2,258,000 after buying an additional 23,584 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics in the first quarter worth about $68,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.